CROSS-DOMAIN PATTERN
Same drug, multiple disease domains
fluoxetine appears in hypotheses across 4 disease domains: Epilepsy, Inflammatory bowel disease, Pancreatic cancer, Type 2 diabetes. Shared mediators that recur across at least two of those domains: TLR7.
Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.
ALL HYPOTHESES
Repurposing candidates for fluoxetine
Epilepsy 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| SERT | high SUDEP risk | 0.208 | Mid | novel signal | none |
Inflammatory bowel disease 2
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| TLR7 | intestinal inflammation | 0.208 | Mid | reproduces known | none | |
| TLR7 | colitis | 0.208 | Mid | reproduces known | none |
Pancreatic cancer 3
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| TLR7 | cell proliferation | 0.208 | Mid | reproduces known | none | |
| TLR7 | good prognosis | 0.208 | Mid | novel signal | none | |
| TLR7 | chemosensitivity | 0.208 | Mid | partial evidence | none |
Type 2 diabetes 1
| Mediator | Outcome | Score | Tier | Lit. status | Trial | |
|---|---|---|---|---|---|---|
| TLR7 | type 1 diabetes | 0.208 | Mid | reproduces known | active |